National institute of allergy and infectious diseases workshop report: “Chlamydia vaccines: the way forward”

Publication date: Available online 31 October 2017
Source:Vaccine
Author(s): Guangming Zhong, Robert C. Brunham, Luis M. de la Maza, Toni Darville, Carolyn Deal
Chlamydia trachomatis (Ct), an intracellular pathogen, is the most common bacterial sexually transmitted infection. In addition to acute cervicitis and urethritis, Ct can lead to serious sequelae of significant public health burden including pelvic inflammatory disease (PID) and infertility. Ct control efforts have not resulted in desired outcomes such as reduced incidence and reinfection, and this highlights the need for the development of an effective Ct vaccine. To this end, NIAID organized a workshop to consider the current status of Ct vaccine research and address critical questions in Ct vaccine design and clinical testing. Topics included the goal(s) of a vaccine and the feasibility of achieving these goals, animal models of infection including mouse and nonhuman primate (NHP) models, and correlates of protection to guide vaccine design. Decades of research have provided both whole cell-based and subunit Ct vaccine candidates for development. At least one is currently in clinical development and efforts now need to be directed towards further development of the most attractive candidates. Overall, the discussions and presentations from the workshop highlighted optimism about the current status of Ct vaccine research and detailed the remaining gaps and questions needed to move Ct vaccines forward.



http://ift.tt/2zWOSKE